Analysis of clinical efficacy and real patient feedback of Sunitinib (Sutent)

Sunitinib (Sunitinib) is a multi-target tyrosine kinase inhibitor (TKI), which mainly acts on VEGFR and PDGFR , KIT and other signaling pathways are widely used in the treatment of advanced renal cell carcinoma, gastrointestinal stromal tumor (GIST) and pancreatic neuroendocrine tumors (pNET). In clinical studies, sunitinib has shown significant anti-tumor effects, not only inhibiting angiogenesis, but also directly inhibiting tumor cell proliferation, thereby prolonging progression-free survival (PFS) and overall survival (OS).

Taking advanced renal cell carcinoma as an example, clinical trial results of sunitinib show that its objective response rate (ORR) is above 30% , which is significantly better than traditional intervention methods. For GIST patients, especially when imatinib is resistant or intolerant, sunitinib has become the second-line standard treatment drug and can significantly delay disease progression. In addition, in the treatment of pNET, sunitinib also demonstrated the effect of inhibiting tumor growth and improving quality of life, providing patients with more treatment options.

Judging from real feedback from patients, many patients who received sunitinib were able to see significant tumor shrinkage or stable lesions during imaging review, and their condition was under control. But at the same time, some patients have reported side effects such as fatigue, stomatitis, skin discoloration, and increased blood pressure. Most adverse reactions were improved through dose reduction or symptomatic treatment under the guidance of doctors, and patient compliance was generally good. It is worth mentioning that many patients believe that the oral administration method of sunitinib is relatively convenient, reducing the burden of hospitalization or frequent medical visits.

Overall, sunitinib as a targeted drug has been clinically proven to have high efficacy and relatively controllable safety, especially in a variety of refractory solid tumors, showing important value. Although some patients will experience side effects, most are manageable and long-term adherence to standardized treatment can often lead to better prognosis. For patients receiving sunitinib treatment, regular follow-up, monitoring of blood pressure and hematological indicators, and adjusting the dosage according to individual conditions are the keys to ensuring efficacy and quality of life.

Reference materials:https://www.drugs.com/